Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisAdedigbo A. Fasanmade, Honghui Zhou, Jewel Johanns et al.|European Journal of Clinical Pharmacology|2009Cited by 322
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseaseMaria Rosario, Irving H. Fox, Walter Reinisch et al.|Alimentary Pharmacology & Therapeutics|2015Cited by 266
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trialsGary Lichtenstein, William J. Sandborn, Robert H. Diamond et al.|Alimentary Pharmacology & Therapeutics|2009Cited by 195
T1132 Pharmacokinetics and Exposure-Response Relationship of Ustekinumab, a Human Monoclonal Antibody to Interleukin 12/23, in Patients with Moderate-to-Severe Crohn's DiseaseAdedigbo A. Fasanmade, Marion Blank, Omoniyi J. Adedokun et al.|Gastroenterology|2008Cited by 2